Benedict Financial Advisors Inc. Sells 1,514 Shares of Novo Nordisk A/S (NYSE:NVO)

Benedict Financial Advisors Inc. cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 38,551 shares of the company’s stock after selling 1,514 shares during the period. Benedict Financial Advisors Inc.’s holdings in Novo Nordisk A/S were worth $3,316,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. International Assets Investment Management LLC increased its holdings in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at $98,765,000. DAVENPORT & Co LLC lifted its position in shares of Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after acquiring an additional 451,641 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $42,017,000. Finally, World Investment Advisors LLC raised its stake in Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after purchasing an additional 270,234 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $86.39 on Friday. The business has a 50-day simple moving average of $91.46 and a two-hundred day simple moving average of $111.51. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The stock has a market cap of $387.66 billion, a PE ratio of 26.26, a PEG ratio of 0.96 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is presently 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.